These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11478490)

  • 21. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.
    Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
    Liver Int; 2011 Oct; 31(9):1359-65. PubMed ID: 21745312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection.
    Polyak SJ; McArdle S; Liu SL; Sullivan DG; Chung M; Hofgärtner WT; Carithers RL; McMahon BJ; Mullins JI; Corey L; Gretch DR
    J Virol; 1998 May; 72(5):4288-96. PubMed ID: 9557719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The nonstructural 5A protein of hepatitis C virus genotype 1b does not contain an interferon sensitivity-determining region.
    Brillet R; Penin F; Hezode C; Chouteau P; Dhumeaux D; Pawlotsky JM
    J Infect Dis; 2007 Feb; 195(3):432-41. PubMed ID: 17205483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is investigation of hepatitis C virus NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis?
    Squadrito G; Raffa G; Restuccia T; Pollicino T; Brancatelli S; Raimondo G
    J Viral Hepat; 2002 Sep; 9(5):360-9. PubMed ID: 12225331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
    Hung CH; Lee CM; Lu SN; Lee JF; Wang JH; Tung HD; Chen TM; Hu TH; Chen WJ; Changchien CS
    J Viral Hepat; 2003 Mar; 10(2):87-94. PubMed ID: 12614464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effect of interferon on hepatitis C virus 1b quasispecies in the nonstructural protein 5A gene.
    Sakuma I; Enomoto N; Kurosaki M; Izumi N; Marumo F; Sato C
    J Infect Dis; 1999 Oct; 180(4):1001-9. PubMed ID: 10479124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.
    Jardim AC; Yamasaki LH; de Queiróz AT; Bittar C; Pinho JR; Carareto CM; Rahal P; Mello IM
    Infect Genet Evol; 2009 Jul; 9(4):689-98. PubMed ID: 19063998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ISDR pattern and evolution in patients with chronic hepatitis C treated with standard or PEG-IFN plus ribavirin.
    Cappiello G; Abbate I; Lo Iacono O; Longo R; Solmone M; Ferraro D; Antonucci G; Di Marco V; Di Stefano R; Craxi A; Ippolito G; Capobianchi MR
    Antivir Ther; 2003 Apr; 8(2):105-10. PubMed ID: 12741622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C.
    Puig-Basagoiti F; Sáiz JC; Forns X; Ampurdanès S; Giménez-Barcons M; Franco S; Sánchez-Fueyo A; Costa J; Sánchez-Tapias JM; Rodés J
    J Med Virol; 2001 Sep; 65(1):35-44. PubMed ID: 11505441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes.
    Frangeul L; Cresta P; Perrin M; Lunel F; Opolon P; Agut H; Huraux JM
    Hepatology; 1998 Dec; 28(6):1674-9. PubMed ID: 9828234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of Hepatitis C Virus NS5A Region Mutation and SNP IL-28B of Host to Support Successful Pegylated Interferon and Ribavirin Treatment in Patients with HCV-HIV Coinfection: A Prospective Cohort Study.
    Kurniawan J; Gani RA; Djauzi S; Ibrahim F; Harimurti K; Nafrialdi N; Imannuel S
    Acta Med Indones; 2019 Apr; 51(2):128-136. PubMed ID: 31383827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in different regions of the genome of hepatitis C virus genotype 1b and association with response to interferon therapy.
    Zhang L; Han F; Zhang D; Dou XG
    Int J Mol Med; 2012 Dec; 30(6):1438-42. PubMed ID: 23064792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterogeneity of HVR-1 quasispecies is predictive of early but not sustained virological response in genotype 1b-infected patients undergoing combined treatment with PEG- or STD-IFN plus RBV.
    Abbate I; Cappiello G; Lo Iacono O; Longo R; Ferraro D; Antonucci G; Di Marco V; Di Stefano R; Craxì A; Solmone MC; Spanò A; Ippolito G; Capobianchi MR
    J Biol Regul Homeost Agents; 2003; 17(2):162-5. PubMed ID: 14518716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection.
    Squadrito G; Orlando ME; Cacciola I; Rumi MG; Artini M; Picciotto A; Loiacono O; Siciliano R; Levrero M; Raimondo G
    J Hepatol; 1999 Jun; 30(6):1023-7. PubMed ID: 10406179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemical response to interferon therapy correlates with interferon sensitivity-determining region in hepatitis C virus genotype 1b infection.
    Yoshioka K; Kobayashi M; Orito E; Watanabe K; Yano M; Sameshima Y; Kusakabe A; Hirofuji H; Fuji A; Kuriki J; Arao M; Murase K; Mizokami M; Kakumu S
    J Viral Hepat; 2001 Nov; 8(6):421-9. PubMed ID: 11703573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.
    Mori N; Imamura M; Kawakami Y; Saneto H; Kawaoka T; Takaki S; Aikata H; Takahashi S; Chayama K;
    J Med Virol; 2009 Apr; 81(4):640-9. PubMed ID: 19235866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations in two PKR-binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness.
    Yokozaki S; Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
    J Med Virol; 2011 Oct; 83(10):1727-32. PubMed ID: 21837788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis.
    Malta Fde M; Medeiros-Filho JE; Azevedo RS; Gonçalves L; Silva LC; Carrilho FJ; Pinho JR
    Mem Inst Oswaldo Cruz; 2010 Feb; 105(1):92-8. PubMed ID: 20209336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
    Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
    Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance.
    Gale MJ; Korth MJ; Katze MG
    Clin Diagn Virol; 1998 Jul; 10(2-3):157-62. PubMed ID: 9741641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.